NASDAQ:MNKD MannKind (MNKD) Stock Price, News & Analysis $4.07 -0.03 (-0.61%) As of 03:23 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MannKind Stock (NASDAQ:MNKD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MannKind alerts:Sign Up Key Stats Today's Range$4.03▼$4.2050-Day Range$2.96▼$4.5252-Week Range$2.23▼$6.51Volume1.75 million shsAverage Volume5.60 million shsMarket Capitalization$1.26 billionP/E RatioN/ADividend YieldN/APrice Target$8.97Consensus RatingModerate Buy Company Overview MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life. Learn more at mannkindcorp.com. Read More MannKind Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreMNKD MarketRank™: MannKind scored higher than 72% of companies evaluated by MarketBeat, and ranked 423rd out of 1,704 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingMannKind has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialMannKind has a consensus price target of $8.97, representing about 120.6% upside from its current price of $4.07.Amount of Analyst CoverageMannKind has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about MannKind's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MannKind are expected to grow in the coming year, from ($0.06) to $0.12 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MannKind is -58.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MannKind is -58.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about MannKind's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.70% of the float of MannKind has been sold short.Short Interest Ratio / Days to CoverMannKind has a short interest ratio ("days to cover") of 4.41.Change versus previous monthShort interest in MannKind has recently decreased by 16.21%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMannKind does not currently pay a dividend.Dividend GrowthMannKind does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.55 News SentimentMannKind has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.89 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for MannKind this week, compared to 5 articles on an average week.Search Interest9 people have searched for MNKD on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.MarketBeat Follows6 people have added MannKind to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MannKind insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,733.00 in company stock.Percentage Held by Insiders2.60% of the stock of MannKind is held by insiders.Percentage Held by Institutions49.55% of the stock of MannKind is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MannKind's insider trading history. Receive MNKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MannKind and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MNKD Stock News HeadlinesMannKind Corporation (MNKD) Up 20% Since Afrezza FDA ApprovalJuly 10, 2026 | finance.yahoo.comMannKind (NASDAQ:MNKD) Upgraded by Wall Street Zen to "Hold" RatingJuly 5, 2026 | americanbankingnews.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.July 16 at 1:00 AM | American Alternative (Ad)MannKind (MNKD) Receives a Grant from Breakthrough T1DJuly 3, 2026 | insidermonkey.comIs MannKind Corporation (MNKD) A Good Stock To Buy Now?June 29, 2026 | finance.yahoo.comMannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1DJune 23, 2026 | globenewswire.comWells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”June 13, 2026 | insidermonkey.comWells Fargo Calls MannKind Corporation (MNKD)’s Commercial Potential a “Show-Me Story”June 13, 2026 | finance.yahoo.comSee More Headlines MNKD Stock Analysis - Frequently Asked Questions How have MNKD shares performed this year? MannKind's stock was trading at $5.67 at the start of the year. Since then, MNKD stock has decreased by 28.3% and is now trading at $4.0650. How were MannKind's earnings last quarter? MannKind Corporation (NASDAQ:MNKD) released its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.02) by $0.03. The business's revenue for the quarter was up 15.1% on a year-over-year basis. Read the conference call transcript. Who are MannKind's major shareholders? Top institutional investors of MannKind include Prodigy Asset Management LLC (0.01%). Insiders that own company stock include Michael Castagna, Stuart A Tross, David Thomson, Steven B Binder and Sanjay R Singh. View institutional ownership trends. How do I buy shares of MannKind? Shares of MNKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MannKind own? Based on aggregate information from My MarketBeat watchlists, some other companies that MannKind investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Bausch Health Cos (BHC), Intel (INTC) and Netflix (NFLX). Company Calendar Last Earnings5/06/2026Today7/16/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 MNKD's financial health is in the Green zone, according to TradeSmith. MNKD has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:MNKD CIK899460 Webwww.mannkindcorp.com Phone(818) 661-5000Fax661-775-2081Employees400Year Founded1991Price Target and Rating Average Price Target for MannKind$8.97 High Price Target$15.00 Low Price Target$4.75 Potential Upside/Downside+118.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.86 million Net Margins-6.63% Pretax Margin-7.92% Return on Equity-11.21% Return on Assets-3.92% Debt Debt-to-Equity RatioN/A Current Ratio1.87 Quick Ratio1.50 Sales & Book Value Annual Sales$348.97 million Price / Sales3.64 Cash Flow$0.07 per share Price / Cash Flow62.70 Book Value($0.17) per share Price / Book-24.21Miscellaneous Outstanding Shares308,950,000Free Float300,917,000Market Cap$1.27 billion OptionableOptionable Beta1.09 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:MNKD) was last updated on 7/16/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredDOJ Admits It In Court—Your Cash Can Be Seized Without WarningThe Department of Justice recently argued in court that cash may not be legally your property - raising concer...Priority Gold | SponsoredYour name isn't on our protected list yetI checked our download records for "The Big Beautiful Bubble Report" and didn't see your name. That concern...American Alternative | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredThe only metrics you should watch as a day trader.Day traders and swing traders don't need the same metrics - and using the wrong ones costs you edge. After 40 ...The TradingPub | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredAmerican’s Biggest Threat Is HereThis feels like one of those ''where were you when Kennedy was shot'' moments. It felt like a moment in time, ...Goldco Direct, LLC | SponsoredALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MannKind Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share MannKind With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
